Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics

1. A compound of formula (I):

in which:

R is

either a hydrogen or halogen atom;

or a phenyl group optionally substituted with one or more halogen atoms, or with one or more groups selected from (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, nitro, amino, di(C 1 -C 3 )alkylamino, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, acetyl or methylenedioxy groups;

or a group selected from pyridinyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, thienyl, furyl, isoxazolyl, isothiazolyl, pyrrolyl and naphthyl, it being possible for this group to be optionally substituted with one or more groups selected from halogen atoms, and (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, trifluoromethoxy, trifluoromethyl, nitro, cyano, hydroxyl, amino, (C 1 -C 6 )alkylamino or di(C 1 -C 6 )alkylamino groups;

or an acid addition salt thereof.

2. The compound of formula (I) according to claim 1 , wherein

R is

either a halogen atom,

or a phenyl group optionally substituted with one or more halogen atoms, or with one or more groups selected from (C 1 -C 6 )alkyl and (C 1 -C 6 )alkoxy groups;

or a group selected from pyridinyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, thienyl, furyl, isoxazolyl, isothiazolyl, pyrrolyl and naphthyl, it being possible for this group to be optionally substituted with one or more (C 1 -C 6 )alkyl groups,

or an acid addition salt thereof.

3. The compound of formula (I) according to claim 1 , wherein

R is

either a halogen atom;

or a phenyl group optionally substituted with one or more halogen atoms, or with one or more groups selected from (C 1 -C 6 )alkyl and (C 1 -C 6 )alkoxy groups;

or a group selected from pyridinyl, pyrazolyl, imidazolyl, thienyl, furyl and pyrrolyl, it being possible for this group to be optionally substituted with one or more (C 1 -C 6 )alkyl groups;

or an acid addition salt thereof.

4. A process for preparing a compound of formula (I) according to claim 1 comprising:

reacting a compound of formula (VII):

either with a boronic acid of formula R—B(OH) 2 in which R is as defined in claim 1 , in the presence of a palladium catalyst;

or with a compound of formula R—H in which R is as defined in claim 1 , in the presence of a strong base in a solvent;

or with a stannous derivative of formula R—Sn[(CH 2 ) 3 CH 3 )] 3 in which R is as defined in claim 1 , in the presence of a palladium catalyst;

or with a compound of formula R—H in which R is as defined in claim 1 , in the presence of n-butyllithium, or zinc chloride or a palladium catalyst.

5. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt, a hydrate or a solvate thereof in combination with at least one pharmaceutically acceptable excipient.

6. A pharmaceutical composition comprising a compound of formula (I) according to claim 2 or a pharmaceutically acceptable salt, a hydrate or a solvate thereof in combination with at least one pharmaceutically acceptable excipient.

7. A pharmaceutical composition comprising a compound of formula (I) according to claim 3 or a pharmaceutically acceptable salt, a hydrate or a solvate thereof in combination with at least one pharmaceutically acceptable excipient.

8. A method of treating cerebral stroke, hypoxic episodes in the brain, or psychiatric pathologies comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof.

9. A method of treating cerebral stroke, hypoxic episodes in the brain, or psychiatric pathologies comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (I) according to claim 2 or a pharmaceutically acceptable salt thereof.

10. A method of treating cerebral stroke, hypoxic episodes in the brain, or psychiatric pathologies comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (I) according to claim 3 or a pharmaceutically acceptable salt thereof.

11. A method of treating pain comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt or a hydrate or a solvate thereof.

12. A method of treating pain comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (I) according to claim 2 or a pharmaceutically acceptable salt or a hydrate or a solvate thereof.

13. A method of treating pain comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (I) according to claim 3 or a pharmaceutically acceptable salt or a hydrate or a solvate thereof.

14. A method of treating lower limb ischemia, obliterative arteritis of the lower limbs, cardiac ischemia, myocardial infarction, heart failure, cutaneous cicatrisation deficiency in diabetic patients, or varicose ulcers in venous insufficiency comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt or a hydrate or a solvate thereof.

15. A method of treating lower limb ischemia, obliterative arteritis of the lower limbs, cardiac ischemia, myocardial infarction, heart failure, cutaneous cicatrisation deficiency in diabetic patients, or varicose ulcers in venous insufficiency comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (I) according to claim 2 or a pharmaceutically acceptable salt or a hydrate or a solvate thereof.

16. A method of treating lower limb ischemia, obliterative arteritis of the lower limbs, cardiac ischemia, myocardial infarction, heart failure, cutaneous cicatrisation deficiency in diabetic patients, or varicose ulcers in venous insufficiency comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (I) according to claim 3 or a pharmaceutically acceptable salt or a hydrate or a solvate thereof.